Angiogenic Proteins: Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.Cysteine-Rich Protein 61: A CCN protein family member that regulates a variety of extracellular functions including CELL ADHESION; CELL MIGRATION; and EXTRACELLULAR MATRIX synthesis. It may play an important role in the development of branched CAPILLARIES during EMBRYOGENESIS.Angiogenesis Inducing Agents: Agents that induce or stimulate PHYSIOLOGIC ANGIOGENESIS or PATHOLOGIC ANGIOGENESIS.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Neovascularization, Physiologic: The development of new BLOOD VESSELS during the restoration of BLOOD CIRCULATION during the healing process.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Vascular Endothelial Growth Factor Receptor-1: A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.Vascular Endothelial Growth Factors: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.Endothelial Growth Factors: These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.Endothelial Cells: Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.Lymphokines: Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity.Fibroblast Growth Factor 2: A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Vascular Endothelial Growth Factor Receptor-2: A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.Angiopoietin-1: The first to be discovered member of the angiopoietin family. It may play a role in increasing the sprouting and branching of BLOOD VESSELS. Angiopoietin-1 specifically binds to and stimulates the TIE-2 RECEPTOR. Several isoforms of angiopoietin-1 occur due to ALTERNATIVE SPLICING of its mRNA.Angiopoietin-2: An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.Pregnancy Proteins: Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)

Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. (1/368)

Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor gene p53 is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here, we investigated the antiangiogenic effect of the wild-type p53 (wt-p53) gene transfer on a human non-small cell lung cancer cell line. Mutant p53-expressing H226Br non-small cell lung cancer cells were transduced with the wt-p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semiquantitative reverse transcription-PCRs for the detection of altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system s.c. transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by s.c. inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor, and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1, resulting in reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wt-p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wt-p53 gene is antiangiogenic, which may explain, in part, the mechanism of the bystander effect induced by the wt-p53 gene transfer on adjacent tumor cells.  (+info)

Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. (2/368)

Vascular endothelial growth factor (VEGF) plays an important role in tumour angiogenesis. VEGF binds to tyrosine kinase receptors, which are expressed almost exclusively on tumour endothelium. Therefore, VEGF can be used to target toxin molecules to tumour vessels for anti-angiogenic therapy. However, recent evidence suggests that VEGF can also bind in an isoform-specific fashion to a newly identified neuropilin-1 (NP-1) receptor. NP-1 is widely expressed in normal tissue and presents a potential target for unwanted toxicity. As a consequence, we investigated whether the VEGF121 isoform, which lacks the NP-1 binding domain, could be used to target toxin polypeptides to tumour vasculature. Treatment of endothelial cells with a VEGF121-diphtheria toxin (DT385) conjugate selectively inhibited proliferating endothelial cells, whereas confluent cultures were completely resistant to the construct. In addition, VEGF121-DT385 conjugate treatment completely prevented tumour cell induced angiogenesis in vivo. Most importantly, the conjugate inhibited tumour growth in athymic mice and induced tumour-specific vascular damage. There was also no apparent toxicity associated with the treatment. Our results suggest that proliferating endothelial cells are highly sensitive to VEGF121-toxin conjugates and that the binding to NP-1 receptors is not necessary for efficient inhibition of tumour growth.  (+info)

Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. (3/368)

The expression of interleukin 10 (IL-10) is correlated with clinical prognosis in non-small cell lung cancer [NSCLC (H. Hatanaka et al., ANN: ONCOL:, 11: 815--819, 2000)]. However, the effects of IL-10 expression on vascularization in NSCLC are not apparent. We examined the gene expression of IL-10/IL-10 receptor and various angiogenic/angioinhibitory factors in 95 NSCLC samples to determine the correlation between IL-10 production and vascularization. Vascular endothelial growth factor, angiopoietin [Ang (Ang-1 and Ang-2)], thrombospondin, brain-specific angiogenesis inhibitor 1, vascular endothelial growth factor receptors (KDR and flt-1), and Ang receptor (TIE2) gene expression were evaluated by reverse transcription-PCR. The cellular localization of these factors and vascularity in the cancer stroma were examined immunohistochemically. Seventy-eight (82.1%) and 93 (97.9%) of these 95 NSCLCs were positive for IL-10 and IL-10 receptor, respectively. Ang-1, Ang-2, and TIE2 gene expression was seen in 76 (97.4%), 73 (93.6%), and 78 (100%) of 78 IL-10-positive NSCLCs, respectively, and was significantly correlated with IL-10 gene expression (P < 0.0088, <0.0008, and 0.0305, respectively; Fisher's exact method). The localizations of Ang-1, Ang-2, and TIE2 were confirmed within tumor cells immunohistochemically. Vascular number and measurement area were significantly higher in the IL-10-positive NSCLCs (33.500 +/- 9.299/microm(2) and 4.742 +/- 1.287%) as compared with IL-10-negative NSCLCs (10.611 +/- 2.839/microm(2) and 0.718 +/- 0.331%; Mann-Whitney U test, P = 0.0039). The IL-10 expression did not show any significant correlation with the expression of other factors. These results suggested that tumor-produced IL-10 promotes stromal vascularization through expression of Ang-1, Ang-2, and TIE2.  (+info)

Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. (4/368)

The brain-specific angiogenesis inhibitor 1 gene has been isolated in an attempt to find fragments with p53 "functional" binding sites. As reported herein and by others, brain-specific angiogenesis inhibitor 1 expression is present in some normal tissues, but is reduced or lost in tumour tissues. Such data and its particular structure prompted the hypothesis that brain-specific angiogenesis inhibitor 1 may act as a mediator in the local angiogenesis balance. We herein demonstrate that brain-specific angiogenesis inhibitor 1 over-expression suppresses tumour angiogenesis, delaying significantly the human tumour growth in immunodeficient mice. The inhibitory effect of brain-specific angiogenesis inhibitor 1 was documented using our intravital microscopy system, strongly implicating brain-specific angiogenesis inhibitor 1 as a mediator in the control of tumour angiogenesis. In contrast, in vitro tumour cell proliferation was not inhibited by brain-specific angiogenesis inhibitor 1 transfection, whereas some level of cytotoxicity was assessed for endothelial cells. Immunohistochemical analysis of tumour samples confirmed a reduction in the microvessel density index in brain-specific angiogenesis inhibitor 1-overexpressing tumours. At messenger level, moderate changes could be detected, involving the down-regulation of vascular endothelial growth factor and collagenase-1 expression. Furthermore, brain-specific angiogenesis inhibitor 1 expression that was lost in a selection of human cancer cell lines could be restored by wild-type p53 adenoviral transfection. Brain-specific angiogenesis inhibitor 1 should be considered for gene therapy and development of efficient drugs based on endogenous antiangiogenic molecules.  (+info)

Selectivity and promiscuity of the first and second PDZ domains of PSD-95 and synapse-associated protein 102. (5/368)

PDZ domains typically interact with the very carboxyl terminus of their binding partners. Type 1 PDZ domains usually require valine, leucine, or isoleucine at the very COOH-terminal (P(0)) position, and serine or threonine 2 residues upstream at P(-2). We quantitatively defined the contributions of carboxyl-terminal residues to binding selectivity of the prototypic interactions of the PDZ domains of postsynaptic density protein 95 (PSD-95) and its homolog synapse-associated protein 90 (SAP102) with the NR2b subunit of the N-methyl-d-aspartate-type glutamate receptor. Our studies indicate that all of the last five residues of NR2b contribute to the binding selectivity. Prominent were a requirement for glutamate or glutamine at P(-3) and for valine at P(0) for high affinity binding and a preference for threonine over serine at P(-2), in the context of the last 11 residues of the NR2b COOH terminus. This analysis predicts a COOH-terminal (E/Q)(S/T)XV consensus sequence for the strongest binding to the first two PDZ domains of PSD-95 and SAP102. A search of the human genome sequences for proteins with a COOH-terminal (E/Q)(S/T)XV motif yielded 50 proteins, many of which have not been previously identified as PSD-95 or SAP102 binding partners. Two of these proteins, brain-specific angiogenesis inhibitor 1 and protein kinase Calpha, co-immunoprecipitated with PSD-95 and SAP102 from rat brain extracts.  (+info)

Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. (6/368)

Brain angiogenesis inhibitors (BAI) are putative transmembrane proteins containing an extracellular domain with thrombospondin type-1 repeats which can exhibit anti-angiogenic activity. BAI1 mRNA is expressed mainly in the brain, while BAI2 and BAI3 mRNAs are more widely expressed. We hypothesized that the BAI family might have anti-tumoral properties and studied the expression of BAI1 protein in normal human brain and in glioblastoma multiforme. We generated an anti-BAI1 antibody and showed that BAI1 was widely expressed in normal brain but was absent in 28 glioma cell lines and in the majority of human glioblastoma investigated. BAI1 expression did not correlate with TP53 status and we did not confirm previous findings that p53 regulates BAI1 mRNA expression in glioma cells. The finding that expression of BAI proteins may be lost during tumor formation is of special interest as restoration of their function in tumors may be of therapeutic benefit.  (+info)

Vascular endothelial growth factor principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. (7/368)

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is essential for bone formation. However, the effect of VEGF on osteoblastic cells during osteoblastogenesis is still controversial. The aim of this study was to clarify the relationship between osteoblastic cells derived from human mesenchymal stem cells (MSCs) and VEGF in the early stage of osteoblastic differentiation. Continuous dexamethasone treatment with a low concentration stimulated osteoblastogenesis of MSCs and the expression of VEGF121 mRNA. The VEGF secretion from osteoblastic cells also increased along with osteoblastogenesis. Neuropilin-1, which mainly binds VEGF165, was detected at all stages during early osteoblastogenesis, but VEGF receptor-1 and -2 were not detected on RT-PCR analyses. In this study, VEGF had no direct effect on the proliferation of osteoblastic cells. However, the secreted VEGF in the conditioned medium of osteoblastic cells exhibited high angiogenic power as to endothelial cell proliferation. Our findings indicated that VEGF121 principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. The present study also demonstrated the differential expression of VEGF121 during osteoblastogenesis. The increase of VEGF in the early stage might be a useful marker of induction of bone formation due to human MSCs.  (+info)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. (8/368)

The serum concentration of two pro-angiogenic cytokines: basic fibroblast growth factor (bFGF) and transforming growth factor beta1 (TGF-beta1), and anti-angiogenic factor endostatin in the serum of 80 never treated B-cell chronic lymphocytic leukemia (CLL) patients and 27 healthy volunteers was measured using an enzyme linked immunosorbent assay. The serum levels of both bFGF and TGF-beta1 were found to be significantly higher in the CLL group (median 40.5 pg/ml and 38.6 ng/ml respectively) when compared to the control group (median 9.4 pg/ml and 18.9 ng/ml, respectively) (p<0.001). The levels of endostatin were not significantly different in CLL and control groups (median 12.3 ng/ml and 8.4 ng/ml, respectively) (p=0.09). In the group of CLL patients the level of bFGF was significantly higher in patients with progressive disease as compared with patients with stable disease (median 90.5 pg/ml and 40.5 pg/ml respectively) (p<0.001). Patients in Rai stage III and IV also had significantly higher levels of bFGF than patients in Rai stage 0-II (median 100.1 pg/ml and 29.3 pg/ml respectively) (p<0.001). The levels of both TGF-beta1 and endostatin were lower in patients in Rai stage III and IV (median 28.9 ng/ml and 9.1 ng/ml respectively) than in patients in Rai stage 0-II (42.8 ng/ml and 13.1 ng/ml respectively) (p<0.001 and p=0.002 respectively). The level of endostatin was also lower in the group of CLL patients with progressive disease (median 10.0 ng/ml) as compared to patients with stable disease (median 20.5 ng/ml) (p=0.008). In conclusion, the disturbance in the balance between pro- and anti-angiogenic factors may have an important influence on the course of CLL.  (+info)

*CYR61

Cysteine-rich angiogenic inducer 61 (CYR61) or CCN family member 1 (CCN1), is a matricellular protein that in humans is encoded ... CCN proteins function as matricellular proteins, which are extracellular matrix proteins that play regulatory roles, ... Other highly conserved homologs were later identified to comprise the CCN protein family (CCN intercellular signaling protein ... "The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and ...

*Soluble fms-like tyrosine kinase-1

... (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein that disables proteins that cause blood ... Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005 ... In contrast, levels of the anti-angiogenic factor sFlt-1 remain stable during the early and middle stages of gestation and ... Both balance in circulating angiogenic factor and blood pressure modulation in pregnancy may be a continuum, with the diagnosis ...

*Vascular endothelial growth factor A

... family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that ... "The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice". Cardiovasc. Res. 86 ... leading to the activation of protein kinase C (PKC). PKC phosphorylates the mitogen-activated protein kinase (MAPK) ERK which ... Vascular endothelial growth factor A (VEGF-A) is a protein that in humans is encoded by the VEGFA gene. This gene is a member ...

*Basic fibroblast growth factor

Pereira RC, Economides AN, Canalis E (Dec 2000). "Bone morphogenetic proteins induce gremlin, a protein that limits their ... Orpana A, Salven P (Feb 2002). "Angiogenic and lymphangiogenic molecules in hematological malignancies". Leukemia & Lymphoma. ... Wu DQ, Kan MK, Sato GH, Okamoto T, Sato JD (Sep 1991). "Characterization and molecular cloning of a putative binding protein ... Skjerpen CS, Nilsen T, Wesche J, Olsnes S (Aug 2002). "Binding of FGF-1 variants to protein kinase CK2 correlates with ...

*Vascular endothelial growth inhibitor

... is protein that in humans is encoded by the TNFSF15 gene. VEGI is an anti-angiogenic protein. It belongs to tumor necrosis ... Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) ... This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this ... It is the sole known ligand for death receptor 3, and it can also be recognized by decoy receptor 3. The protein encoded by ...

*Benjamin P. Sachs

Circulating angiogenic proteins trisomy 12 Am J Obstet Gynecol. 2006 Jan:194(1):239-45 Sachs BP, A Woman with Fetal Loss - ... Circulating Angiogenic Factors and the Risk of Preeclampsia. NEJM 2004; 350:672-83 Levine RJ, Thadhani R, Qian C, Lam C, Lim KH ... a novel circulating anti-angiogenic factor in preeclampsia. N Engl J Med 2006;355:992-1005 Nielsen P, Goldman M, Mann S, ...

*Angiogenesis

In contrast, pro-angiogenic protein therapy uses well-defined, precisely structured proteins, with previously defined optimal ... which angiogenic research began with, and pro-angiogenic therapies. Whereas anti-angiogenic therapies are being employed to ... Until 2007, three human clinical trials have been successfully completed with FGF-1, in which the angiogenic protein was ... Chemical stimulation of angiogenesis is performed by various angiogenic proteins, including several growth factors. The ...

*Placental growth factor

... an angiogenic protein, at 2.0 A resolution". The Journal of Biological Chemistry. 276 (15): 12153-61. doi:10.1074/jbc. ... Placental growth factor is a protein that in humans is encoded by the PGF gene. Placental growth factor (PGF) is a member of ... Placental growth factor (PGF) is a protein-coding gene and a member of the vascular endothelial growth factor (VEGF) family. ... Roberts-Clark DJ, Smith AJ (November 2000). "Angiogenic growth factors in human dentine matrix". Archives of Oral Biology. 45 ( ...

*Diabetic retinopathy

This protection appears to be due to the elevated levels of endostatin, an anti-angiogenic protein, derived from collagen XVIII ... An experimental study suggests that the pericyte death is caused by blood glucose persistently activating protein kinase C and ... mitogen-activated protein kinase (MAPK), which through a series of intermediates inhibits signaling through platelet-derived ...

*Pre-eclampsia

Angiogenic proteins such as vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) and anti-angiogenic ... sFlt-1 is an anti-angiogenic protein that antagonizes vascular endothelial growth factor (VEGF) and placental growth factor ( ... Proteinuria ≥ 0.3 grams (300 mg) or more of protein in a 24-hour urine sample or a SPOT urinary protein to creatinine ratio ≥ ... Implicit in this generalized endothelial dysfunction may be an imbalance of angiogenic and anti-angiogenic factors. Both ...

*Asif Ahmed (scientist)

... as an inhibitor of anti-angiogenic proteins (soluble Flt-1 and soluble endoglin) Soluble Flt-1, the natural anti-VEGF factor in ... Professor Ahmed identified soluble Flt-1 as the single most important molecule responsible for the angiogenic imbalance in ... was amongst the first to signal the importance of vascular growth factors in pregnancy and pioneered the concept of angiogenic ... preeclampsia by demonstrating that the removal of soluble Flt-1 from preeclamptic samples restored angiogenic balance which was ...

*List of MeSH codes (D12.644)

... angiogenic proteins MeSH D12.644.276.100.100 --- angiopoietins MeSH D12.644.276.100.100.100 --- angiopoietin-1 MeSH D12.644. ... rap gtp-binding proteins MeSH D12.644.360.525.475.100 --- rap1 gtp-binding proteins MeSH D12.644.360.525.500 --- ras proteins ... grb2 adaptor protein MeSH D12.644.360.024.298 --- grb7 adaptor protein MeSH D12.644.360.024.300 --- grb10 adaptor protein MeSH ... 14-3-3 proteins MeSH D12.644.360.024.318 --- proto-oncogene proteins c-crk MeSH D12.644.360.024.326 --- proto-oncogene proteins ...

*CCN protein

The CCN protein family includes the following six proteins: CCN1: CYR61 (cysteine-rich angiogenic protein 61) CCN2: CTGF ( ... Together with three Wnt-induced secreted proteins, they comprise the CCN family of matricellular proteins. These proteins have ... CCN proteins are a family of extracellular matrix (ECM)-associated proteins involved in intercellular signaling. Due to their ... cysteine-rich angiogenic protein 61 or CCN1), CTGF (connective tissue growth factor or CCN2), and NOV (nephroblastoma ...

*List of MeSH codes (D23)

... angiogenic proteins MeSH D23.348.479.311.100 --- angiopoietins MeSH D23.348.479.311.100.100 --- angiopoietin-1 MeSH D23.348. ... hiv core protein p24 MeSH D23.050.327.520.330 --- hiv envelope protein gp41 MeSH D23.050.327.520.350 --- hiv envelope protein ... adenovirus e1 proteins MeSH D23.050.327.045.060 --- adenovirus e2 proteins MeSH D23.050.327.045.070 --- adenovirus e3 proteins ... ldl-receptor related protein 2 MeSH D23.050.422.500.750 --- ldl-receptor related protein-associated protein MeSH D23.050. ...

*Angiopoietin-related protein 1

... a unique angiopoietin-related protein with anti-angiogenic properties". Biochem. Biophys. Res. Commun. 333 (2): 308-15. doi: ... This protein was found to be a secretory protein that does not act as an endothelial cell mitogen in vitro. GRCh38: Ensembl ... Angiopoietin-related protein 1 also known as angiopoietin-3 (ANG-3) is a protein that in humans is encoded by the ANGPTL1 gene ... 1999). "Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein ...

*Proteases in angiogenesis

These effects are mediated by interacting and interfering with various angiogenic related proteins such as integrins and serine ... "Structure-function analysis of the ADAM family of diintegrin-like and metalloproteinase-containing proteins". J. Protein Chem. ... Native proteins which contain such domains with regulatory activity are normally inactive, most likely because they are cryptic ... Monocytes produce a variety of pro-angiogenic factors. There is also a population of CD34 positive cells that can express ...

*CXCL1

"The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma". J. Leukoc. Biol. 67 (1): 53-62. PMC 2669312 . PMID ... neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α). In humans, this protein is ... for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins ...

*Syndecan 1

"HIV-tat protein is a heparin-binding angiogenic growth factor". Oncogene. 12 (2): 289-97. PMID 8570206. Bonaldo MF, Lennon G, ... Syndecan 1 is a protein which in humans is encoded by the SDC1 gene. The protein encoded by this gene is a transmembrane (type ... The syndecan-1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and ... Indatuximab ravtansine targets this protein. It is a useful marker for plasma cells, but only if the cells tested are already ...

*Syndecan-4

"HIV-tat protein is a heparin-binding angiogenic growth factor". Oncogene. 12 (2): 289-97. PMID 8570206. Kojima T, Katsumi A, ... The protein is found as a homodimer and is a member of the syndecan proteoglycan family. Syndecan-4 interacts with ... Syndecan-4 is a protein that in humans is encoded by the SDC4 gene. Syndecan-4 is one of the four vertebrate syndecans and has ... Syndecan-4 activates protein kinase C (PKC), an enzyme involved in signal transduction. The variable domain of syndecan-4 could ...

*NOV (gene)

... cysteine-rich angiogenic inducer 61, or CCN1), CTGF (connective tissue growth factor, or CCN2), and NOV. These proteins, ... is a novel angiogenic regulator of the CCN protein family". The Journal of Biological Chemistry. 278 (26): 24200-8. doi:10.1074 ... The human NOV protein contains 357 amino acids with an N-terminal secretory signal peptide followed by four structurally ... Perbal B, Martinerie C, Sainson R, Werner M, He B, Roizman B (Feb 1999). "The C-terminal domain of the regulatory protein NOVH ...

*Stem-cell niche

The angiogenic switch downregulates angiogenesis suppressor proteins, such as thrombospondin, angiostatin, endostatin and ... GSCs are easily identified through histological staining against vasa protein (to identify germ cells) and 1B1 protein (to ... Angiogenesis induced by hypoxic conditions is called an "Angiogenic switch". HIF-1 promotes expression of several angiogenic ... But there is evidence that the expression of angiogenic agens by cancer cells can also be HIF-1 independent. It seems that ...

*Syndecan-3

1996). "HIV-tat protein is a heparin-binding angiogenic growth factor". Oncogene. 12 (2): 289-97. PMID 8570206. Chernousov MA, ... Hakansson S, Jacobs A, Caffrey M (2001). "Heparin binding by the HIV-1 tat protein transduction domain". Protein Sci. 10 (10): ... Syndecan-3 is a protein that in humans is encoded by the SDC3 gene. GRCh38: Ensembl release 89: ENSG00000162512 - Ensembl, May ... "Entrez Gene: SDC3 syndecan 3". Barillari G, Gendelman R, Gallo RC, Ensoli B (1993). "The Tat protein of human immunodeficiency ...

*Coronary artery disease

Numerous clinical trials were performed, either applying protein (angiogenic growth factor) therapies, such as FGF-1 or VEGF, ... Wagoner L.E.; Merrill W.; Jacobs J.; Conway G.; Boehmer J.; Thomas K.; Stegmann T.J. (2007). "Angiogenesis Protein Therapy With ... High levels of lipoprotein(a), a compound formed when LDL cholesterol combines with a protein known as apolipoprotein(a). ... Research efforts are focused on new angiogenic treatment modalities and various (adult) stem-cell therapies. A region on ...

*EGLN1

These gene products may include proteins such as glycolytic enzymes and angiogenic growth factors. In normoxia, HIF alpha ... 1996). "SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle". Lab. Invest. 74 ( ... Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2), or prolyl hydroxylase domain-containing protein 2 (PHD2), is an enzyme ... 2006). "Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia- ...

*Thrombospondin 1

"Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity". The Journal ... This protein is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. This protein can bind to ... "Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell ... the remaining anti-angiogenic domains have been shown to have decreased anti-angiogenic activity at low concentrations where ...

*Proto-oncogene tyrosine-protein kinase Src

Zan L, Zhang X, Xi Y, Wu H, Song Y, Teng G, Li H, Qi J, Wang J (2013). "Src regulates angiogenic factors and vascular ... The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by CSK. ... This protein phosphorylates specific tyrosine residues in other proteins. An elevated level of activity of c-Src tyrosine ... c-Src can be activated by many transmembrane proteins that include: adhesion receptors, receptor tyrosine kinases, G-protein ...

*Lee Byung-heon (biochemist)

Nam, J. O.; Jung, M. Y.; Thapa, N.; Lee, B. H.; Park, R. W.; Kim, I. S. (2008). "T-CAM, a fastatin-FIII 9-10 fusion protein, ... potently enhances anti-angiogenic and anti-tumor activity αvβ3 and α5β1 integrins". Experimental & Molecular Medicine. 40 (2): ... Nam, J. -O.; Son, H. -N.; Jun, E.; Cha, K.; Lee, B. -H.; Park, R. -W.; Kim, I. -S. (2012). "FAS1 Domain Protein Inhibits ... Thapa, N.; Lee, B. H.; Kim, I. S. (2007). "TGFBIp/βig-h3 protein: A versatile matrix molecule induced by TGF-β". The ...
View mouse Baiap2 Chr11:119942763-120006782 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
BAI2 antibody (brain-specific angiogenesis inhibitor 2) for IHC-P. Anti-BAI2 pAb (GTX71911) is tested in Human samples. 100% Ab-Assurance.
BAP3 was initially identified through interaction in a yeast two-hybrid system with the brain-specific angiogenesis inhibitor 1, a p53-target gene that encodes a seven-span transmembrane protein member of the secretin receptor family. BAP3 is predominantly expressed in the brain and possess high homology with Munc13 and synaptotagmin, suggesting that BAP3 may play a role in regulating neurotransmitter release. Recent experiments have shown that BAP3 is induced in certain tumors such as desmoplastic small round cell tumor. Ectopic expression of BAP3 in tumor cells dramatically enhances growth in low serum conditions and colony formation in soft agar, suggesting that the regulated exocytotic pathway may play a role in cancer cell proliferation. BAP3 is known to have two isoforms; this BAP3 antibody will recognize only isoform 2. Lower molecular weight bands may represent cleavage or degradation products. ...
This is the first report that Del-1 is expressed in adult animals in response to ischemia and that it plays an important role in adult angiogenesis. The protein encoded by Del-1 plays a critical role in embryonic vascular development. However, at the time of birth, the gene becomes quiescent, and Del-1 is no longer expressed in normal adult tissues.. In the embryo, Del-1 is expressed by endothelial progenitor cells and is secreted into the extracellular matrix.1 Del-1 supports adherence and migration of endothelial cells, mediated largely through the αvβ3 integrin receptor. Accumulating evidence indicates that angiogenesis requires signaling through both growth factor and integrin signaling pathways. Endothelial cells deprived of either influence will undergo programmed cell death.12 Indeed, in the chick CAM assay, antibodies directed against αvβ3 suppress Del-1-induced angiogenesis.13 A mutant form of Del-1, when the RGD motif has been altered (RGD→RAD), also disrupts angiogenesis in this ...
The energy requirements of the brain are large and immediate. The need to deliver adequate oxygen and glucose and to remove carbon dioxide specifies the vascular architecture. Taken as a whole, the...
Bai Yue is a medicine available in a number of countries worldwide. A list of US medications equivalent to Bai Yue is available on the Drugs.com website.
0005] One embodiment of the invention provides a method of detecting cancer or a predisposition to developing cancer in a subject. The method comprises determining an expression level of a cancer-associated polynucleotide, protein, or polypeptide selected from the group consisting of Titin; HBA1; Insulin-like growth factor 1 receptor (IGF1R); Isoform 3 of zonadhesin precursor; latent transforming growth factor beta binding protein 4 (LTBP4); ASXL1 (additional sex combs like 1); beta globin (HBB); BMP15-bone morphogenetic protein; TRIM49; DNAJ homolog subfamily B member 11 precursor; uncharacterized hematopoietic stem/progenitor cells protein MDS027; uncharacterized protein ALB; isoform 3 of sushi, nidogen and EGF-like domain-containing protein 1 precursor; isoform 2 of peripherin; mitochondrial 28S ribosomal protein S22; translation initiation factor EIF-2B subunit epsilon; estradiol 17-beta-dehydrogenase 1; XRCC6BP1; brain-specific angiogenesis inhibitor 1 precursor; isoform 2 of ring finger ...
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 is an enzyme that in humans is encoded by the MAGI1 gene. The protein encoded by this gene is a member of the membrane-associated guanylate kinase homologue (MAGUK) family. MAGUK proteins participate in the assembly of multiprotein complexes on the inner surface of the plasma membrane at regions of cell-cell contact. The product of this gene may play a role as scaffolding protein at cell-cell junctions. Alternatively spliced transcript variants encoding different isoforms have been identified. MAGI1 has been shown to interact with: ACCN3, ATN1, Actinin alpha 4, Beta-catenin, Brain-specific angiogenesis inhibitor 1, Calcium-activated potassium channel subunit alpha-1, FCHSD2, LRP2, and SYNPO. ENSG00000151276 GRCh38: Ensembl release 89: ENSG00000282956, ENSG00000151276 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000045095 - Ensembl, May 2017 "Human PubMed Reference:". "Mouse PubMed Reference:". Shiratsuchi T, ...
The ultimate goal of this proposal is to understand the contribution of Vstat120 expressing oncolytic viruses on OV propagation, tumor biology and anti-tumor ef...
In addition to being a proangiogenic factor in endothelial cells, Aggf1 has yet to be fully explored in the context of human pathophysiology. We present evidence here that Aggf1 plays a role in maintaining the contractile phenotype of SMCs, in part, by stabilizing the SRF-myocardin complex. It is not clear exactly how Aggf1 modulates the SRF-myocardin interaction although there exist several probable scenarios. Aggf1 is a novel binding partner for myocardin (Figure 3A). Many previously characterized myocardin-associated factors either stabilize or disrupt the SRF-myocardin complex.8 It is likely that Aggf1 may function as a scaffold to bring SRF and myocardin together. Alternatively, the ability of myocardin to associate with SRF is known to be modulated by post-translational modifications.8,17 It has recently been shown that Aggf1 is able to modulate the activities of several kinases including extracellular signal-regulated kinase18 and Akt12 although Aggf1 overexpression did not seem to alter ...
Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Sigma-Aldrich offers abstracts and full-text articles by [Maosheng Zhan, Yumiko Hori, Naoki Wada, Jun-Ichiro Ikeda, Yuuki Hata, Keigo Osuga, Eiichi Morii].
Anat Rec (Hoboken). 2013 Aug;296(8):1161-8. doi: 10.1002/ar.22676. Epub 2013 Jun 6. Comparative Study; Research Support, Non-U.S. Govt
Christensen, A C M and Haresign, W and Khalid, M (2014) Progesterone exposure of seasonally anoestrous ewes alters the expression of angiogenic growth factors in preovulatory follicles. Theriogenology, 81 (2). pp. 358-367. ...
Therapeutic angiogenesis remains a worthy but somewhat elusive clinical goal. Attempts to increase blood flow to ischemic tissue have included a variety of physical and biological approaches. A growing understanding of the cells and proteins involved in vessel sprouting and maturation led to a number of genetic approaches aimed at promoting angiogenesis in ischemic myocardium and skeletal muscle. In spite of several strategies undergoing testing in clinical trials, the delivery of vectors encoding for single growth factors has not yet shown clinical efficacy. In response to these challenges, a number of groups have aimed to provide multiple angiogenic factors for ischemic tissue. These approaches include gene transfer of transcription factors that regulate multiple angiogenic peptides (such as hypoxia inducible factor-1 ) or transplantation of cells capable of providing a regulated source of secreted growth factors and cytokines. A potential advantage of delivered cells is that they may also directly
4942 Elevated tumor cyclooxygenase 2 (COX-2) activity plays a multifaceted role in non-small cell lung cancer (NSCLC). To elucidate the role of COX-2 in the in vitro and in vivo expression of two known NSCLC angiogenic peptides, CXCL8 and CXCL5, we studied two COX-2 gene modified NSCLC cell lines, A549 and H157. COX-2 overexpression enhanced the in vitro expression of both CXCL8 and CXCL5. In contrast, specific COX-2 inhibition decreased the in vitro production of both peptides. Consistent with the COX-2 in vitro effects, the enhanced tumor growth of COX-2 expressing tumors in a SCID-mouse model of NSCLC was accompanied by elevated levels of CXCL5 and CXCL8. Furthermore, neutralizing anti-CXCL5 and anti-CXCL8 antisera inhibited the tumor growth of COX-2 overexpressing tumors in SCID-mice. In addition, the COX-2 related angiogenic capacity of H157 was efficiently reduced by anti-CXCR2 treatment in a rat corneal pocket model of angiogenesis. In summary, we conclude that COX-2 contributes to the ...
Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis.: The angiogenic peptide adrenomedullin
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
VG5Q functions as an angiogenic factor in promoting angiogenesis and suppression of VG5Q expression inhibits vessel formation. Angiogenic factors are…
Qian Bai is a medicine available in a number of countries worldwide. A list of US medications equivalent to Qian Bai is available on the Drugs.com website.
Definition of angiogenic gene therapy in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is angiogenic gene therapy? Meaning of angiogenic gene therapy as a finance term. What does angiogenic gene therapy mean in finance?
Preeclampsia is the onset of high blood pressure and proteinuria that acutely develops after about 20 weeks of pregnancy, which impairs fetal growth and can result in maternal organ damage. There are few treatment options available. Oxidative stress mediated by reactive oxygen species (ROS) has been proposed to inhibit blood vessel formation (a process called angiogenesis) in the placenta, which would be expected to increase the risk of preeclampsia; however, clinical trials have found antioxidants to be ineffective in preventing preeclampsia. Nezu et al. used a mouse model of preeclampsia in which the antioxidant system Nrf2 had been genetically or pharmacologically manipulated. Unexpectedly, genetic ablation of an inhibitor of Nrf2 or treatment with an activator of Nrf2 decreased placental angiogenesis, suppressed fetal growth, and worsened maternal survival. In contrast, deficiency of Nrf2 increased placental angiogenesis and improved fetal and maternal outcomes. These results indicate that ...
We have previously shown that intracoronary delivery of recombinant adenoviruses encoding angiogenic proteins that contain signal peptides (fibroblast growth factor-4 and fibroblast growth factor-5) ameliorate myocardial ischemia. In the present paper, we test the hypothesis that the presence of the signal peptide is an important element in the favorable effects that transgene expression has on regional flow and function in an animal model of myocardial ischemia. We performed intracoronary delivery of two different recombinant adenoviruses encoding a fibroblast growth factor-2 variant, one with a signal peptide, FGF-2LI(+sp), and one without a signal peptide, FGF-2LI(-sp). In a model of stress-induced myocardial ischemia, intracoronary injection of these recombinants resulted in mRNA and protein expression of the transferred gene. Two weeks after gene transfer, regional abnormalities in stress-induced function and blood flow were improved after delivery of FGF-2LI containing the signal peptide. ...
A novel angiogenic composition obtained from the omentum is provided which acts as a potent and effective factor for blood perfusion enhancement and for the development of new blood vessels in an organized structural network in living tissues. The angiogenic composition is a lipid or lipids, essentially protein-free as extracted from the omentum using organic solvents. This composition can then be injected to target to a site where new blood vessel formation, or blood perfusion enhancement is required. This material can be used to heal various damaged tissues including bone and heart.
PRIMARY OBJECTIVES:. I. To evaluate the response rate of chemotherapy-refractory sarcomas to 20 mg per day of single-agent Ang(Angiotensin)-(1-7) or 10 mg per day of single-agent Ang-(1-7) if excessive toxicity is observed at the 20 mg dose.. II. To evaluate toxicities associated with single-agent Ang-(1-7) when given to patients with chemotherapy-refractory sarcomas.. SECONDARY OBJECTIVES:. I. To assess time to progression (TTP) and overall survival (OS) in patients treated with Ang-(1-7).. II. To evaluate accumulation of Ang-(1-7) after 21 days of continuous treatment and quantify changes in plasma levels of angiogenic peptides including placental growth factor (PlGF).. OUTLINE:. Patients receive therapeutic angiotensin-(1-7) subcutaneously (SC) once daily in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. ...
Advanced St IIIB/IV NS-NSCLC p with ECOG 0-2 prospectively included and treated 1st-line with CP-Bev 6 cycles followed by Bev maintenance. Primary end-point: PFS; secondary end-points: OS, RR, toxicity. Ancillary study designed to investigate relationship between angiogenic mediators, response and outcomes. Ethical approval and informed consent for collecting peripheral blood samples and associated clinical data. Samples collected before treatment (basal) and at response evaluation (post). DNA obtained from leukocyte fraction. SNPs of angiogenic genes genotyped by PCR. Plasma levels of VEGFA and VEGFR2 determined by ELISA. Response RECIST.1 and toxicity CTCAEv.1. ...
We investigated whether the angiogenic profile, which is based on the local expression and systemic levels of angiogenic growth factors (VEGF, Ang-1, Ang-2, and the corresponding receptors), differs between rheumatoid arthritis (RA) and osteoarthritis (OA) patients. We determined the expression of VEGF, Ang-1, and Ang-2 together with its receptors (VEGFR-1/-2 ...
Vrei să arati bine si să te simti bine? Alege o cura de slabire, un machiaj sau o coafura nouă. Magazinul nostru online iti ofera tot ce ai bai de ovaz in psoriazis. Cura de slabire www. Publicat de forma maxima la Trimiteți prin bai de ovaz in psoriazis Postați pe blog!. Distribuiți pe Twitter Distribuiți pe Facebook Trimiteți către Pinterest. Desi te vei gandi ca magazinele sunt pline de cadouri, te poti insela deoarece acestea bai de ovaz in psoriazis sunt unice si nu se pot personaliza. Daca esti in pana de idei sau daca vrei sa oferi bai de ovaz in psoriazis deosbeit, care se impresioneze cu siguranta, alege o bijuterie handmade personalizata pentru persoana iubita din viata ta.. Fie ca sunt membri ai familiei, fie ca ca sunt bai de ovaz in psoriazis de serviciu sau sefi, un cadou inscriptionat cu un mesaj bine ales sau gravat cu o imagine sugestiva va face o impresie deosebita asupra celui care il primeste.. Bratarile se inscriu in mai multe categorii, bai de ovaz in psoriazis ...
Sigma-Aldrich offers abstracts and full-text articles by [M C Ramello, J Tosello Boari, F P Canale, H A Mena, S Negrotto, B Gastman, A Gruppi, E V Acosta Rodríguez, C L Montes].
Klippel-Trenaunay syndrome is a birth (congenital) condition that affects the development of blood vessels, soft tissue and bones.
Klippel-Trenaunay syndrome is a birth (congenital) condition that affects the development of blood vessels, soft tissue and bones.
PDT is being successfully used in clinics for the treatment of superficial lesions of both malignant and non-malignant diseases. However, treating solid tumors is still a challenge due to issues related to penetration of light, non-homogeneity and geometry of the tumors [21]. Triggering of angiogenesis is also dependent on different PDT parameters such as drug/light dosage and drug light interval. Previous studies have shown that sub-optimal PDT elicits increased angiogenesis [22, 23]. In our earlier study we have reported that high dose light PDT with high fluence rate induces the overexpression of VEGF compared to low dose light PDT [24]. We have also noticed that predominantly cellular targeting long drug light interval PDT can induce greater expression of angiogenic proteins compared to vascular targeting short drug light interval PDT [25]. Therefore, there is a need for continued investigation to enhance the anti-tumor efficacy of PDT for improved response and expanded use. In this study, ...
Introduction: We have previously shown that treatment with epidermacan a novel stem cell derived paracrine factor promoted angiogenesis in vitro accompanied with an increase in angiogenic miRNA expression. Here, we identified novel microRNAs regulated by epidermacan and validated their importance in modulating the epidermacan angiogenic effects in vitro and in vivo.. Methods and Results: Increased levels of pro-angiogenic miRNAs such as miR-10b, miR-21 and miR-424 were discovered in MicroRNA profiling of HUVEC cells treated with epidermacan and then confirmed by qRT-PCR. We also identified miR-874, a relatively unknown miRNA but for its role as a tumor suppressor. Investigation of the downstream microRNA/gene networks revealed that epidermacan regulated known angiogenic genes such as VEGFC, TBX1, HIF-1a and NRP1. Importantly, treatment with epidermacan decreased the levels of HoxD10, a known target of miR-10b in thrombin induced angiogenesis. Inhibition of miR-10b or miR-874 via anti-miR ...
Low expressions of angiogenic growth factors delay the healing of diabetic wounds by interfering with the process of blood vessel formation. Heparin mimetic peptide nanofibers can bind to and enhance production and activity ...
Sierra-Honigmann, M.R., Nath, A.K., Murakami, C., Garcia-Cardena, G, Papapetropoulos, A., Sessa, W.C., Madge, L.A., Schechner, J.S., Schwabb, M.B., Polverini, P.J., and Flores-Riveros, J.R. (1998) Biological action of leptin as an angiogenic factor. Science 281:1683-1686 ...
Effect on healing Time of parameter variations.(a): Healing time versus angiogenic strain threshold, γangio (X signifies the prediction of non-union) (b): Heal
Read about the journeys of our patients with Klippel-Trenaunay Syndrome from experts at Boston Childrens, ranked best Childrens Hospital by US News.
Timely regulated changes in oxygen partial pressure are important for placental formation. Disturbances could be responsible for pregnancy-related diseases like preeclampsia and intrauterine growth restriction. We aimed to (i) determine the effect of oxygen partial pressure on cytotrophoblast differentiation; (ii) measure mRNA expression and protein secretion from genes associated with placental angiogenesis; and (iii) determine the reversibility of these effects at different oxygen partial pressures. Term cytotrophoblasts were incubated at 21% and 2.5% O2 for 96 hr, or were switched between the two oxygen concentrations after 48 hr. Real-time PCR and enzyme-linked immunosorbent assays (ELISAs) were used to evaluate cell fusion and differentiation, measuring transcript levels for those genes involved in cell fusion and placental angiogenesis, including VEGF, PlGF, VEGFR1, sVEGFR1, sENG, INHA, and GCM1. Cytotrophoblasts underwent fusion and differentiation in 2.5% O2 . PlGF expression was ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Publishers, "Placental Growth Factor (PIGF) Blockers-Pipeline Insights, 2016″, report provides in depth insights on the pipeline drugs and their development activities around the Placental Growth Factor (PIGF) Blockers. The Publishers Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publishers Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Placental Growth Factor (PIGF) Blockers. Publishers Report also assesses the Placental Growth Factor (PIGF) Blockers therapeutics by Monotherapy, Combination products, Molecule type and ...
Angiogenesis is the formation of new blood vessels from existing vasculature. Vascular Endothelial Growth Factor (VEGF), a known angiogenic protein, stimulates endothelial cell proliferation and migration via interactions with its receptors, KDR and Flt-1. A secreted form of Flt-1 (sFlt-1), derived from alternatively-spliced RNA, can inhibit actions of VEGF in vivo. It has been suggested that alterations in sFlt-1 expression could significantly change the angiogenic VEGF activity. This project focuses on characterizing intronic elements that regulate Flt-1 mRNA splicing. A "wild-type" construct (pFIN13), containing the first 13 exons, intron 13 and exons 14-30 of mouse Flt-1, was shown to produce both forms of Flt-1 mRNA after transfection into HEK293 cells. To gauge the strength of the native splicing signals in intron 13 of Flt-1, a series of point mutations were made in the polypyrimidine tract using pFIN13. After transient transfection, the levels of Flt-1 and sFlt-1 protein and mRNA were ...
Endometriosis is a chronic, inflammatory disease characterized by the growth of endometrial tissue in aberrant locations outside the uterus. Neoangiogenesis or establishment of new blood supply is one of the fundamental requirements of endometriotic lesion survival in the peritoneal cavity. IL-17A is emerging as a potent angiogenic and proinflammatory cytokine involved in the pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis and psoriasis. However, sparse information is available in the context of endometriosis. In this study, we demonstrate the potential importance of IL-17A in the pathogenesis and pathophysiology of endometriosis. The data show a differential expression of IL-17A in human ectopic endometriotic lesions and matched eutopic endometrium from women with endometriosis. Importantly, surgical removal of lesions resulted in significantly reduced plasma IL-17A concentrations. Immunohistochemistry revealed localization of IL-17A primarily in the stroma ...
Cancer Therapy Advisor provides pediatricians with the latest information to correctly diagnose the latest child medical disorder conditions, recommend procedures and guides. Visit often for updates and new information.
A family of structurally-related angiogenic proteins of approximately 70 kDa in size. They have high specificity for members of the TIE RECEPTOR FAMILY ...
Angiogenesis is a multicellular morphogenesis process that expands vascular networks in tissue. Various biological components concertedly contribute to angiogenic morphogenesis. The most important cellular component is endothelial cells, which we use to reconstruct 3D angiogenic process in a extracellular matrix in response to angiogenic growth factors. In addition, perivascular pericytes, blood flow and extravascular tissue importantly serve as (sub)components that allow constructing more sophisticated vascular networks. However, a mechanistic understanding of how the individual components contribute to various angiogenic processes is largely missing. In this seminar, I will introduce a reconstitution angiogenesis assay system with a microfluidic device that allows dissecting the phenomenon in a bottom-up way by adding individual components to the essential one. I will discuss the roles of pericyte and intraluminal pressure on angiogenic morphogenesis based on recent unpublished data obtained ...
Blood vessel formation. Artwork showing malignant (cancerous) tumour cells promoting the formation of new blood vessels, a process known as angiogenesis. The tumour cells release angiogenic growth factor proteins that bind to endothelial cells in nearby blood vessels and encourage the growth of new blood vessels from the existing ones. These blood vessels provide the tumour with oxygen and nutrients. - Stock Image C026/8534
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
Principal Investigator:MAEKAWA Hisato, Project Period (FY):1998 - 1999, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Gastroenterology
ANGPT2 (Human) ELISA Kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human ANGPT2. (KA1867) - Products - Abnova
INTRODUCTION Stimulation of coronary collateral vessel growth by therapeutic angiogenesis (TA) offers an alternative treatment option for patients with refractory angina. Several TA modalities, including delivery to the heart of angiogenic growth factors (proteins or genes) and cells have been tested in clinical trials in the past two decades, but so far none of them resulted in significant therapeutic efficacy in large scale studies. This review attempts to identify the main obstacles hindering clinical success and recommends measures to overcome them in the future. AREAS COVERED After stating the medical need and rational for TA, and listing and briefly discussing past and current TA clinical trials, three main areas of obstacles are described: conceptual questions, technical limitations and clinical design uncertainties. Based on scientific and technical advances and lessons learned in past clinical trials, potential solutions to overcome some of these obstacles are proposed. EXPERT OPINION
Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis ). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP
The present study reveals two mechanisms by which UFH and LMWH affect angiogenesis in vitro. UFH and LMWH inhibit the proliferation of hMVECs induced by the angiogenic factors bFGF and VEGF165 to a similar degree, and differently affect fibrin matrix formation. LMWH causes the formation of more rigid fibrin matrices that inhibit capillary-like tubular structure formation, whereas UFH contributes to the formation of a more porous fibrin matrix and thus facilitates angiogenesis.. Angiogenesis is required for the expansion of many solid tumors and facilitates the metastasis of tumor cells to other organs (10) . Factors altering angiogenesis may, therefore, influence these processes and thereby the prognosis of cancer patients. Various studies have suggested that heparins affect the proliferation of endothelial cells by their effects on angiogenic growth factors, in particular FGFs and VEGFs (35 , 36) . Both endothelial heparan sulfates and heparins can promote the interaction of these growth ...
Rezulin (Troglitazone or Tro or T), a glitazone PPAR-gamma agonist, was approved for treatment of type 2 diabetes mellitus, but was withdrawn from the market due to idiosyncratic liver toxicity. Two similar drugs, Avandia (Rosiglitazone or Rosi or R) and Actos (Pioglitazone or Pio or P), are considered to be safe treatments for the same condition. The expression profile of key drug metabolism genes should be different in cells treated with Rezulin versus those treated with Avandia and Actos.. Hepatocellular carcinoma HepG2 cells were treated at 80% cell confluence with these three drugs (100 µM, Cayman Chemical) or a DMSO vehicle control for 24 h. RNA isolated using the ArrayGrade™ Total RNA Isolation Kit was used to characterize gene expression with the Human Drug Metabolism and Stress & Toxicity PathwayFinder™ RT² Profiler™ PCR Arrays and RT² SYBR Green / Fluorescein PCR master mix on the Bio-Rad iCycler®.. ...
Síndrome de Parkes Weber (SPW) é uma rara malformação vascular congênita, semelhante à Síndrome de Klippel-Trenaunay, mas tendo suas próprias características distintas. Ela foi descrita pela primeira vez em 1907 pelo dermatologista britânico Frederick Parkes Weber. Ela só é encontrada em cerca de 0,3% da população mundial. A SPW é caracterizada por malformações venosas e anomalias capilares cutâneas semelhantes às da Síndrome de Klippel-Trenaunay juntamente com uma malformação arteriovenosa. Malformações linfáticas são raras. Também pode incluir hipertrofia esquelética e/ou dos tecidos moles. A síndrome pode afetar vários membros, o tronco e a cabeça. O tronco e as extremidades inferiores são mais comumente afetados. A característica mais comum da SPW são malformações capilares, também conhecidas como manchas em vinho do Porto. Seu aspecto é de uma mácula avermelhada, que escurece ao longo dos anos. Malformações capilares são lesões de baixo fluxo ...
The present study demonstrated the validity and superiority of CD105 as a marker of angiogenesis in NSCLC; the CD105-IMVD was more closely correlated with the expression of VEGF than the CD34-IMVD. Kumar et al. (11 , 13 , 15, 16, 17, 18) and others have demonstrated that anti-CD105 antibodies preferentially react with activated ECs in tissues participating in angiogenesis, such as tumor tissues, and that antibodies against pan-ECs, such as anti-CD34 antibodies, react with normal vessels, as well as activated vessels. According to the hypothesis, we tried to define the CD34-IMVD-CD105-IMVD as the baseline IMVD. As a result, the baseline IMVD proved not at all to be correlated with VEGF expression, suggesting the baseline IMVD was not a measurement of angiogenesis but a measurement of vessels just trapped within tumor tissues. Of course, it should be noted that angiogenesis is not influenced only by VEGF but also other angiogenic factors and antiangiogenic factors, such as angiostatin. Comparative ...
Phenotypical signature of pro-angiogenic TEM.(A) In vivo corneal vascularization assay to assess the pro-angiogenic activity of TEM isolated from peripheral blo
购买我们的人ELMO2肽。ab22879可作为ab2240的封闭肽并经过Blocking实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。
UOC di Otorinolaringoiatria, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione di Caserta. ABSTRACT. Klippel-Trenaunay syndrome (KTS) is a rare congenital disorder characterized by capillary malformations (port-wine stains or flat haemangiomas), soft tissue and bone hypertrophy, large varicose veins. Intracranial vascular malformations are very rare. The Authors report a case of a 4 year old girl with KTS, suffering from anacusis in the left ear and severe sensorineural hearing loss in the right ear, who underwent cochlear implantation; in our case angiomatous formations were located inside the temporal bone, one of these adherent to the vertical portion of the facial nerve.. INTRODUCTION. In 1900 Maurice Klippel and Paul Trenaunay were the first to describe a rare angio-osteoipertrofica syndrome characterized by symptom triad: capillary malformations (port-wine stains or flat hemangiomas), soft tissue and bone hypertrophy, large varicose veins (1, 2). It typically affects one ...
Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein that disables proteins that cause blood vessel growth. Soluble Flt-1 (sFlt-1) is a splice variant of VEGF receptor 1 (Flt-1) which is produced by a variety of tissues.These proteins act as a receptor of vascular endothelial growth factor (VEGF), a potent angiogenic growth factor. (Another VEGF receptor is KDR). sFlt-1 (soluble fms-like tyrosine kinase-1 - also known as soluble VEGF receptor-1) binds and reduces free circulating levels of the proangiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor). sFlt-1 thereby blunts the beneficial effects of these proangiogenic factors on maternal endothelium, with consequent maternal hypertension and proteinuria. Serum levels of PlGF and sFlt-1 are altered in women with preeclampsia. Moreover, circulating levels of PlGF and sFlt-1 can discriminate between a normal pregnancy and that with preeclampsia even prior to clinical ...
Purpose : Placental growth factor (PlGF) and vascular endothelial growth factor B (VEGF-B) are members of the vascular endothelial growth factor family, binding to VEGF-R1. PIGF inhibition suppresses pathological angiogenesis in inflammatory disorders and diabetic retinas. PIGF levels are overexpressed in the vitreous of diabetic retinopathy (DR) patients and levels may increase with the severity of the disease. VEGF-B is a vascular survival factor, safeguarding the balance between blood vessel growth and degeneration. Under degenerative conditions VEGF-B is a survival factor to protect cells from apoptosis; during certain pathologies can act as antiangiogenic factor to prevent overgrowth of blood vessels. Angiogenic VEGF-B activity during ocular neovascularization may be due to its survival effect, rescuing neovessels from apoptosis. Vitreous VEGF-B levels are significantly increased in DR patients. The purpose of this study was to correlate vitreous angiogenic cytokines (VEGF-B and PIGF) ...
Alternative titles; symbols KTW SYNDROME KLIPPEL-TRENAUNAY SYNDROME; KTS ANGIOOSTEOHYPERTROPHY SYNDROMEGene map locus 5q13.3 TEXT A number sign (#) is used with this entry because at least some cases of Klippel-Trenaunay syndrome are caused by mutation in or gain-of-function translocation involving the VG5Q gene (608464). The features of Klippel-Trenaunay-Weber syndrome are large cutaneous hemangiomata with hypertrophy of the related bones and soft tissues. The disorder resembles, clinically and in its lack of definite genetic basis, Sturge-Weber syndrome (185300), and indeed the 2 have been associated in some cases (Harper, 1971). Suggestions of a genetic cause are meager (Waardenburg, 1963). See 116860. Lindenauer (1965) described brother and sister. He suggested that when arteriovenous fistula is also present, the disorder is distinct from the KTW syndrome and might be called Parkes Weber syndrome, since Weber (1907) described cases of this type as well as cases seemingly identical to those ...
First we focused on the function of the TMD23 portion of rTM used for treatment. Previously, domain 23 has been considered an angiogenic factor,30 promoting mouse cutaneous wound healing through modulating angiogenesis at the wound site.38,39 Thus, to determine whether the anti-inflammatory effects we observed were because of a possible angiogenic effect of rTM containing domains 23, classic angiogenic molecule VEGF, and its R1 and R2 receptor proteins, were measured in the infected cornea in rTM-treated and control mice. The VEGF protein did not differ at either 3 or 5 days p.i., while the level of R1 was slightly elevated at 3 and reduced at 5 days; R2 levels were unchanged at 3 and reduced at 5 days p.i. after rTM treatment. Because numerous molecules are angiogenic and it would be impossible to test all of them, India ink35,36 was used to globally assess the angiogenic potential of the 23 domain contained in rTM. Visual, followed by statistical analysis of these data showed no difference ...
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a decisive role for the rapid growth of avian follicles. Compared to mammals, few data on the angiogenesis in the avian ovary are available. However, whereas several pro-angiogenic factors in the avian ovary have been recently studied in detail, little information is available on the localization of anti-angiogenic factors. The aim of this study was to determine the localization and possible function of the anti-angiogenic factor thrombospondin-1 (TSP-1) and its receptor CD36 in the ovary of the ostrich using immunohistochemistry and to correlate the results with ultrastructural data ...
Compensatory angiogenic signaling pathways. Although VEGF is likely the predominant angiogenic factor in human tumors, it is clear from preclinical and clinical studies with VEGF-targeted agents that tumors can grow despite inhibition of the VEGF pathway. These observations led to the hypothesis that compensatory mechanisms for tumor angiogenesis may account for inherent or acquired resistance to VEGF-targeted therapy. The fibroblast growth factor (FGF) family of ligands was the first resistance mechanism identified. In an elegant study done in the Hanahan laboratory, the investigators showed that treatment with an anti-VEGF R-2 mAb was associated with a decrease in vascular density after 10 days of treatment with an anti-VEGFR2 antibody (20). However, these investigators noted an angiogenic rebound in tumors at 4 weeks that was associated with an increase in expression of redundant angiogenic factors, including members of the FGF family. By using a FGF-trap, these investigators were able to ...
CRC is the third most common cancer worldwide, and in the European Union alone, the lifetime estimated risk of developing the disease is 6%. Over the last 30 years, advances in diagnostic tools and a consensus towards internationally standardised staging criteria of the condition, together with combined multimodal treatment strategies, have contributed to substantial improvement in 5 year survival rates for patients with CRC, from 22% to 50% [42]. Crucially, recent advances in understanding molecular mechanisms driving tumours have increased our understanding of the mechanisms underlying the benefits of new treatment agents which selectively target abnormal pathways confined to tumours, allowing improvements in the prognosis of patients with advanced CRC and development of new therapeutic modalities.. Deciphering the complex biological mechanisms underlying tumour angiogenesis has been a major focus of research, as the growth of solid tumours is restricted to 2-3 mm3 in size without ...
In this study, we showed for the first time that RAGE is involved in impaired angiogenic response in diabetes. Moreover, our results implicate esRAGE as a therapeutic factor to protect impaired angiogenic response in diabetes. In addition to the vasodegenerative changes (2-4), several observations indicated that angiogenic response or development of new vessels in response to local ischemia/inflammation is significantly reduced in diabetic patients and animals (5-8). However, only few reports showed the involvement of AGEs/RAGE system in diabetic-related impaired angiogenesis. Goova et al. (19) demonstrated that blockade of RAGE restores effective wound healing in diabetic mice. Tamarat et al. (18) demonstrated that blockade of AGE formation restored ischemia-induced angiogenesis in diabetic mice. Both of these reports implicate the functional role of AGEs in impaired angiogenic response but do not necessarily delineate the role of RAGE. Goova et al.s (19) observation is made by using sRAGE, a ...
Purified Recombinant Human ANGPT1/COMP protein, FLAG-tagged from Creative Biomart. Recombinant Human ANGPT1/COMP protein, FLAG-tagged can be used for research.
Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis may take place in two ways - endothelial sprouting or non-sprouting (intussusceptive).
Lots of letters huh?I read some interesting info a few other blogs in the past few days about nuts and thought I would post more on fatty acid sources because that is what we will be discussing in class tomorrow afternoon ( again!)I have this chart from my biochemistry book of the make up of…
The aim of this study was to determine if diffusible angiogenic growth factors were released in human dental pulp during orthodontic tooth movement. These factors, if diffusible, could induce angiogenesis in other tissues, and may then be isolated and identified. The pulps from 14 premolar teeth treated with straight wire fixed orthodontic appliances for 2 weeks were compared with those of 14 untreated control premolar teeth from the same subjects. Following tooth extraction and sectioning, 1-mm horizontal sections of pulp tissue were embedded in collagen with l-mm sections of rat aorta and co-cultured in growth media for up to 4 weeks. Sections of rat aorta alone were also cultured. Angiogenic changes in the form of microvessel growth were observed by light microscopy. Microvessel identification was confirmed by electron microscopy and by immunohistochemistry using staining for factor VIII-related antigen marker for endothelial cells.. When compared at days 5, 10 and 14 of co-culture, the ...
Multiple mechanisms have been implicated in the pathogenesis of DN, including modification and inactivation of proteins critical to neural function by nonenzymatic glycosylation,8 altered neural polyol metabolism,6,7 reductions in neurotrophin or the availability of neurotrophic factors, and microvascular disease including reduced vasa nervora in the diabetic nerve.20,35 However, debate still oscillates between propositions based on neurochemical versus vascular events. Our data demonstrate that not only neurotrophic factors but also various angiogenic cytokines were significantly reduced in the diabetic sciatic nerves. These data reveal that downregulation of both neurochemical and of vascular factors is related to the development of DN. After injection of SHh, expression of the Gli-1 transcription factor was upregulated and the expression of multiple endogenous angiogenic cytokines (angiopoietin-1, angiopoietin-2, and VEGF-1) and neurotrophic factors (BDNF and IGF-1) was restored to ...
The ability to form new skeletal muscle capillaries in ischemic tissue is a major challenge. The concept that new blood vessels can grow to enhance tissue perfusion is now achieving widespread acceptance.20 Therapeutic angiogenesis is proposed as a complement or an alternative to surgical revascularization. To date, several proangiogenic factors, including VEGF and fibroblast growth factor, have been tested and have demonstrated convincing efficiency in acute and chronic experimental models21; however, clinical trials to test VEGF or fibroblast growth factor angiogenic therapy in coronary and peripheral artery diseases were disappointing because their effects were inconsistent.21,22 One of the explanations for the lack of efficiency of angiogenic therapy probably comes from the use of individual factors, whereas angiogenesis is known to involve a plethora of angiogenic factors.. On the basis of their previous data, Matsakas et al19 propose in this issue of Circulation Research a new and very ...
As reported in this weeks JAMA, low urine levels of placental growth factor seem to predict preeclampsia before other typical clinical signs of the condition become apparent.
购买我们的重组人PLGF蛋白。Ab84148为全长蛋白,在HEK 293细胞中生产并经过SDS-PAGE实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://jinxiuwang.net.insight.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://haochuduo.net.insight.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://chinatell.cn.insight.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://xianhuamh.net.insight.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... We also identified inhibitor of DNA binding protein 2 (ID2) as a key upstream regulator of KDR activation during myeloid ...
more infohttps://gimee-gz.com.www.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://tianshangmodel.cn.www.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... Blockade of the angiogenic response by inhibition of VEGF-C signaling lessened the development of inflammation and airway ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Our findings identify that lung endothelium and PACs in the airway sense allergen and elicit an angiogenic response that is ...
more infohttps://earnflying.net.insight.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://taoyantao.com.www.mobile.jci.org/tags/12

JCI -
WelcomeJCI - Welcome

Subsequent surges in MCT stimulated retinal endothelial cells to produce monocyte chemotactic protein-1 (MCP1) and angiogenic ... EMC3 was essential for the processing and routing of surfactant proteins, SP-B and SP-C, and the biogenesis of the phospholipid ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ... Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis ...
more infohttps://oktaikong.com.www.mobile.jci.org/tags/12

Early anti-angiogenic proteins expression in amniotic fluid of twin fetuses.Early anti-angiogenic proteins expression in amniotic fluid of twin fetuses.

Multiple pregnancies are thought to be associated with a high incidence of perinatal complications such as preterm labor, preeclampsia and low birth weight. But the true mechanisms of these obstetric complications are still uncertain. The components
more infohttp://www.biomedsearch.com/nih/Early-anti-angiogenic-proteins-expression/21962138.html

Inflammatory and Angiogenic Protein Detection in the Human Vitreous: Cytometric Bead AssayInflammatory and Angiogenic Protein Detection in the Human Vitreous: Cytometric Bead Assay

... M. J. Koss, M. Pfister, and F. H. ... M. J. Koss, M. Pfister, and F. H. Koch, "Inflammatory and Angiogenic Protein Detection in the Human Vitreous: Cytometric Bead ...
more infohttps://www.hindawi.com/journals/joph/2011/459251/cta/

Developmental Endothelial Locus-1 (Del-1), a Novel Angiogenic Protein | CirculationDevelopmental Endothelial Locus-1 (Del-1), a Novel Angiogenic Protein | Circulation

Developmental Endothelial Locus-1 (Del-1), a Novel Angiogenic Protein. Its Role in Ischemia. Hoai-Ky V. Ho, James J. Jang, ... Mutation of the RGD to RAD sequence reduces its angiogenic effect in the CAM assay to one third of that of the native protein. ... Developmental Endothelial Locus-1 (Del-1), a Novel Angiogenic Protein. Hoai-Ky V. Ho, James J. Jang, Shuichiro Kaji, Gary ... Developmental Endothelial Locus-1 (Del-1), a Novel Angiogenic Protein. Hoai-Ky V. Ho, James J. Jang, Shuichiro Kaji, Gary ...
more infohttp://circ.ahajournals.org/content/109/10/1314

Angiogenic protein expression in advanced epithelial ovarian cancer. | Clinical Cancer ResearchAngiogenic protein expression in advanced epithelial ovarian cancer. | Clinical Cancer Research

Angiogenic protein expression in advanced epithelial ovarian cancer.. D P Barton, A Cai, K Wendt, M Young, A Gamero and S De ... Angiogenic protein expression in advanced epithelial ovarian cancer.. D P Barton, A Cai, K Wendt, M Young, A Gamero and S De ... Angiogenic protein expression in advanced epithelial ovarian cancer.. D P Barton, A Cai, K Wendt, M Young, A Gamero and S De ... Angiogenic protein expression in advanced epithelial ovarian cancer. Message Subject (Your Name) has forwarded a page to you ...
more infohttp://clincancerres.aacrjournals.org/content/3/9/1579

A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane.  - PubMed - NCBIA heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. - PubMed - NCBI

A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane.. Folkman J1, ... The sequestration of angiogenic endothelial mitogens in the basement membrane may be a general mechanism for regulating their ... The basement membranes of bovine cornea are found to contain an angiogenic endothelial cell mitogen, basic fibroblast growth ... These findings indicate that basement membranes of the cornea may serve as physiologic storage depots for an angiogenic ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/3277442?dopt=Abstract

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib ...Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib ...

Plasma angiogenic proteins were evaluated as potential PD biomarkers of response to lenvatinib in a dose-escalation phase 1 ... PD biomarker changes observed in plasma angiogenic proteins are correlated with lenvatinib-induced tumor shrinkage and AEs. Our ... Blood samples for plasma proteins were collected on days 1 (baseline), 8, and 15 of cycle 1, and days 1, 8, and 15 of cycle 2. ... findings warrant further assessment of plasma proteins associated with angiogenesis as potential biomarkers of lenvatinib ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-530

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib ...Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib ...

Plasma angiogenic proteins were evaluated as potential PD biomarkers of response to lenvatinib in a dose-escalation phase 1 ... PD biomarker changes observed in plasma angiogenic proteins are correlated with lenvatinib-induced tumor shrinkage and AEs. Our ... Blood samples for plasma proteins were collected on days 1 (baseline), 8, and 15 of cycle 1, and days 1, 8, and 15 of cycle 2. ... findings warrant further assessment of plasma proteins associated with angiogenesis as potential biomarkers of lenvatinib ...
more infohttps://www.semanticscholar.org/paper/Pharmacodynamic-change-in-plasma-angiogenic-a-phase-Koyama-Saito/4d124a14dc7756f4e78b0ec77c44b1df1ed8c7b8

The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients...The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients...

... and with angiogenic proteins was examined in patients administered drugs with anti-angiogenic activity. Blood was collected ... Blood levels of specific angioregulatory miRs are not associated with levels of angiogenic proteins. miRs warrant further ... and plasma angiogenic proteins, by enzyme linked immunosorbent assays. Levels of miR-199a were positively correlated and miR- ... Angiogenic proteins also did not change significantly with treatment. Blood levels of specific angioregulatory miRs are ...
more infohttps://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-241

The Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway | Cancer ResearchThe Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway | Cancer Research

The Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway. Yugang Wang, ... The Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway ... The Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway ... The Unfolded Protein Response Induces the Angiogenic Switch in Human Tumor Cells through the PERK/ATF4 Pathway ...
more infohttp://cancerres.aacrjournals.org/content/72/20/5396

Porcine Cyr61 (Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit Manufacturers in DelhiPorcine Cyr61 (Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit Manufacturers in Delhi

Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit OSCAR DIAGNOSTIC SERVICES PVT. LTD.is an India based Company in Delhi. ... Porcine Cyr61 (Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit » Porcine Cyr61 (Cysteine Rich Protein, Angiogenic ... Porcine Cyr61 (Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit. Porcine Cyr61 (Cysteine Rich Protein, Angiogenic ... Porcine Cyr61 (Cysteine Rich Protein, Angiogenic Inducer 61) ELISA Kit. Porcine Cyr61 (Cysteine Rich Protein, Angiogenic ...
more infohttps://www.odspl.com/sub-product/Porcine+Cyr61+%28Cysteine+Rich+Protein%2C+Angiogenic+Inducer+61%29+ELISA+Kit.php

Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity | JCBPeptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity | JCB

Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. SS Tolsma, OV ... Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity ... The definition of short peptides from each of these domains that are able to block the angiogenic process may be of use in ... The majority of the anti-angiogenic activity of TSP1 resides in the central 70-kD stalk region which alone could block ...
more infohttp://jcb.rupress.org/content/122/2/497?ijkey=ea73e11e0e85c921c25ca3bfac150029f19f6568&keytype2=tf_ipsecsha

An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype -- Ngo et al. 11 (4): 201 -- Cell...An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype -- Ngo et al. 11 (4): 201 -- Cell...

An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype. 1 Cam V. Ngo, Michael Gee, Nasim ... Genomic targets of the human c-Myc protein. Genes & Dev., May 1, 2003; 17(9): 1115 - 1129. [Abstract] [Full Text] [PDF] ... These data suggest that Myc is fully competent to trigger the angiogenic switch in vivo and that secondary events may not be ... The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes & Dev., September 15, 2006; 20(18): 2527 ...
more infohttp://cgd.aacrjournals.org/cgi/content/abstract/11/4/201

Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial...Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial...

Smith, J. R., David, L., Appukuttan, B., & Wilmarth, P. (Accepted/In press). Angiogenic and Immunologic Proteins Identified by ... Smith, JR, David, L, Appukuttan, B & Wilmarth, P 2018, Angiogenic and Immunologic Proteins Identified by Deep Proteomic ... Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial ... Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial ...
more infohttps://ohsu.pure.elsevier.com/en/publications/angiogenic-and-immunologic-proteins-identified-by-deep-proteomic-

Plus itPlus it

Measurement of angiogenic proteins with a human angiogenesis array kit. The experiment was performed according to the ... The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of ... To determine whether the enhanced VM formation ability in MDMA was related to the endogenous angiogenic factors, we performed ... USP44 KD at the protein level was achieved by USP44 shRNA compared with the control. I, following USP44 KD, the percentage of ...
more infohttp://mct.aacrjournals.org/content/14/9/2121

Development and pathologies of the arterial wall.  - PubMed - NCBIDevelopment and pathologies of the arterial wall. - PubMed - NCBI

Angiogenic Proteins. Grant support. *2T32HL007950/HL/NHLBI NIH HHS/United States. *5K08HL093362/HL/NHLBI NIH HHS/United States ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?term=24071897
  • The association of blood levels of microRNAs (miRs) implicated in angiogenesis with circulating endothelial cells (CEC) and with angiogenic proteins was examined in patients administered drugs with anti-angiogenic activity. (biomedcentral.com)
  • 1990). To determine which of the structural motifs present in the 180-kD TSP1 polypeptide mediate the anti-angiogenic activity, a series of protease-generated fragments were tested using several in vitro and in vivo assays that reflect angiogenic activity. (rupress.org)
  • The majority of the anti-angiogenic activity of TSP1 resides in the central 70-kD stalk region which alone could block neovascularization induced by bFGF in the rat cornea in vivo and inhibit both migration in a modified Boyden chamber and [3H]thymidine incorporation stimulated by bFGF in cultured capillary endothelial cells. (rupress.org)
  • We hypothesize that GD induces the angiogenic switch in tumors through activation of the unfolded protein response (UPR). (aacrjournals.org)
  • First, how MDA-7 protein is regulated as tumors develop from benign moles to the full-blown skin cancer known as melanoma and secondly, how over-expression of the mda-7 gene will affect melanoma cancer cell growth. (bio-medicine.org)
  • In the scientific publication, the researchers conclude that the MDA-7 protein is present in normal melanocytes (cells responsible for pigmentation in the skin) and early stages of melanoma tumors. (bio-medicine.org)
  • The definition of short peptides from each of these domains that are able to block the angiogenic process may be of use in designing targeted inhibitors of the pathological neovascularization that underlies many diseases. (rupress.org)
  • Previously, recombinant proteins consisting of suppressor of cytokine signaling 3 (SOSC3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. (freepatentsonline.com)
  • Porcine serum albumin was used as control for unspecific protein effects. (chalmers.se)
  • No significant sprouting was observed with the non-specific protein control porcine serum albumin or medium only. (chalmers.se)
  • Several studies have focused on known protein mediators of angiogenic processes. (biomedcentral.com)
  • In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. (freepatentsonline.com)
  • Physiologic and pathologic neovascularization in other tissues may also be initiated by release of stored angiogenic factors from the basement membrane. (nih.gov)
  • Previously developed hydrophobic CPPs-named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD)-are able to deliver biologically active proteins into a variety of cells and tissues. (freepatentsonline.com)
  • Thrombospondin-1 (TSP1) is a large modular matrix protein containing three identical disulfide-linked 180-kD chains that inhibits neovascularization in vivo (Good et al. (rupress.org)
  • An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype -- Ngo et al. (aacrjournals.org)
  • Furthermore, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. (freepatentsonline.com)
  • These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. (freepatentsonline.com)
  • This result is comparable to the positive control, fibronectin, an ECM protein involved in all phases of tissue repair. (chalmers.se)
  • p>An evidence describes the source of an annotation, e.g. an experiment that has been published in the scientific literature, an orthologous protein, a record from another database, etc. (uniprot.org)
  • Peptide sequences were assigned to fragment ion spectra, and proteins were inferred from openly accessible protein databases. (elsevier.com)
  • Blood samples for plasma proteins were collected on days 1 (baseline), 8, and 15 of cycle 1, and days 1, 8, and 15 of cycle 2. (biomedcentral.com)
  • Blood levels of specific angioregulatory miRs are not associated with levels of angiogenic proteins. (biomedcentral.com)
  • A number of drugs with anti-angiogenic effects are in common use to treat cancer, and a number are under investigation. (biomedcentral.com)
  • Taken together, the present observations suggest that the angiogenic effects might be explained by the cell binding properties of amelogenin. (chalmers.se)
  • Angiogenic proteins also did not change significantly with treatment. (biomedcentral.com)
  • The formin family protein CaBni1p has a role in cell polarity control during both yeast and hyphal g. (biomedsearch.com)